Global Clinical Oncology Next Generation Sequencing (NGS) Market Research Report 2023

Report ID: 1992026 | Published Date: Sep 2024 | No. of Page: 110 | Base Year: 2023 | Rating: 4.9 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
        1.2.2 NGS Pre-Sequencing
        1.2.3 Sequencing
        1.2.4 NGS Data Analysis
        1.2.5 Primary, Secondary & Tertiary Data Analysis
    1.3 Market by Application
        1.3.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Growth by Application: 2018 VS 2022 VS 2029
        1.3.2 Academic & Clinical Research
        1.3.3 Hospitals & Clinics
        1.3.4 Pharma & Biotech Entities
    1.4 Study Objectives
    1.5 Years Considered
    1.6 Years Considered
2 Global Growth Trends
    2.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Perspective (2018-2029)
    2.2 Clinical Oncology Next Generation Sequencing (NGS) Growth Trends by Region
        2.2.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region: 2018 VS 2022 VS 2029
        2.2.2 Clinical Oncology Next Generation Sequencing (NGS) Historic Market Size by Region (2018-2023)
        2.2.3 Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Region (2024-2029)
    2.3 Clinical Oncology Next Generation Sequencing (NGS) Market Dynamics
        2.3.1 Clinical Oncology Next Generation Sequencing (NGS) Industry Trends
        2.3.2 Clinical Oncology Next Generation Sequencing (NGS) Market Drivers
        2.3.3 Clinical Oncology Next Generation Sequencing (NGS) Market Challenges
        2.3.4 Clinical Oncology Next Generation Sequencing (NGS) Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Clinical Oncology Next Generation Sequencing (NGS) Players by Revenue
        3.1.1 Global Top Clinical Oncology Next Generation Sequencing (NGS) Players by Revenue (2018-2023)
        3.1.2 Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Players (2018-2023)
    3.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Clinical Oncology Next Generation Sequencing (NGS) Revenue
    3.4 Global Clinical Oncology Next Generation Sequencing (NGS) Market Concentration Ratio
        3.4.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Clinical Oncology Next Generation Sequencing (NGS) Revenue in 2022
    3.5 Clinical Oncology Next Generation Sequencing (NGS) Key Players Head office and Area Served
    3.6 Key Players Clinical Oncology Next Generation Sequencing (NGS) Product Solution and Service
    3.7 Date of Enter into Clinical Oncology Next Generation Sequencing (NGS) Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Clinical Oncology Next Generation Sequencing (NGS) Breakdown Data by Type
    4.1 Global Clinical Oncology Next Generation Sequencing (NGS) Historic Market Size by Type (2018-2023)
    4.2 Global Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Type (2024-2029)
5 Clinical Oncology Next Generation Sequencing (NGS) Breakdown Data by Application
    5.1 Global Clinical Oncology Next Generation Sequencing (NGS) Historic Market Size by Application (2018-2023)
    5.2 Global Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Application (2024-2029)
6 North America
    6.1 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size (2018-2029)
    6.2 North America Clinical Oncology Next Generation Sequencing (NGS) Market Growth Rate by Country: 2018 VS 2022 VS 2029
    6.3 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2018-2023)
    6.4 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2024-2029)
    6.5 United States
    6.6 Canada
7 Europe
    7.1 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size (2018-2029)
    7.2 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Growth Rate by Country: 2018 VS 2022 VS 2029
    7.3 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2018-2023)
    7.4 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2024-2029)
    7.5 Germany
    7.6 France
    7.7 U.K.
    7.8 Italy
    7.9 Russia
    7.10 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size (2018-2029)
    8.2 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Growth Rate by Region: 2018 VS 2022 VS 2029
    8.3 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region (2018-2023)
    8.4 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region (2024-2029)
    8.5 China
    8.6 Japan
    8.7 South Korea
    8.8 Southeast Asia
    8.9 India
    8.10 Australia
9 Latin America
    9.1 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size (2018-2029)
    9.2 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Growth Rate by Country: 2018 VS 2022 VS 2029
    9.3 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2018-2023)
    9.4 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2024-2029)
    9.5 Mexico
    9.6 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size (2018-2029)
    10.2 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Growth Rate by Country: 2018 VS 2022 VS 2029
    10.3 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2018-2023)
    10.4 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2024-2029)
    10.5 Turkey
    10.6 Saudi Arabia
    10.7 UAE
11 Key Players Profiles
    11.1 Illumina
        11.1.1 Illumina Company Detail
        11.1.2 Illumina Business Overview
        11.1.3 Illumina Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.1.4 Illumina Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
        11.1.5 Illumina Recent Development
    11.2 Roche
        11.2.1 Roche Company Detail
        11.2.2 Roche Business Overview
        11.2.3 Roche Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.2.4 Roche Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
        11.2.5 Roche Recent Development
    11.3 Agilent Technologies
        11.3.1 Agilent Technologies Company Detail
        11.3.2 Agilent Technologies Business Overview
        11.3.3 Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.3.4 Agilent Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
        11.3.5 Agilent Technologies Recent Development
    11.4 Knome
        11.4.1 Knome Company Detail
        11.4.2 Knome Business Overview
        11.4.3 Knome Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.4.4 Knome Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
        11.4.5 Knome Recent Development
    11.5 Genomatix Software
        11.5.1 Genomatix Software Company Detail
        11.5.2 Genomatix Software Business Overview
        11.5.3 Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.5.4 Genomatix Software Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
        11.5.5 Genomatix Software Recent Development
    11.6 GATC Biotech
        11.6.1 GATC Biotech Company Detail
        11.6.2 GATC Biotech Business Overview
        11.6.3 GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.6.4 GATC Biotech Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
        11.6.5 GATC Biotech Recent Development
    11.7 Oxford Nanopore Technologies
        11.7.1 Oxford Nanopore Technologies Company Detail
        11.7.2 Oxford Nanopore Technologies Business Overview
        11.7.3 Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.7.4 Oxford Nanopore Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
        11.7.5 Oxford Nanopore Technologies Recent Development
    11.8 Macrogen
        11.8.1 Macrogen Company Detail
        11.8.2 Macrogen Business Overview
        11.8.3 Macrogen Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.8.4 Macrogen Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
        11.8.5 Macrogen Recent Development
    11.9 Life Technologies
        11.9.1 Life Technologies Company Detail
        11.9.2 Life Technologies Business Overview
        11.9.3 Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.9.4 Life Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
        11.9.5 Life Technologies Recent Development
    11.10 DNASTAR
        11.10.1 DNASTAR Company Detail
        11.10.2 DNASTAR Business Overview
        11.10.3 DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.10.4 DNASTAR Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
        11.10.5 DNASTAR Recent Development
    11.11 Exosome Diagnostics
        11.11.1 Exosome Diagnostics Company Detail
        11.11.2 Exosome Diagnostics Business Overview
        11.11.3 Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.11.4 Exosome Diagnostics Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
        11.11.5 Exosome Diagnostics Recent Development
    11.12 Biomatters
        11.12.1 Biomatters Company Detail
        11.12.2 Biomatters Business Overview
        11.12.3 Biomatters Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.12.4 Biomatters Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
        11.12.5 Biomatters Recent Development
    11.13 CLC Bio
        11.13.1 CLC Bio Company Detail
        11.13.2 CLC Bio Business Overview
        11.13.3 CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.13.4 CLC Bio Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
        11.13.5 CLC Bio Recent Development
    11.14 BGI
        11.14.1 BGI Company Detail
        11.14.2 BGI Business Overview
        11.14.3 BGI Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.14.4 BGI Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
        11.14.5 BGI Recent Development
    11.15 Qiagen
        11.15.1 Qiagen Company Detail
        11.15.2 Qiagen Business Overview
        11.15.3 Qiagen Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.15.4 Qiagen Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
        11.15.5 Qiagen Recent Development
    11.16 Perkin Elmer
        11.16.1 Perkin Elmer Company Detail
        11.16.2 Perkin Elmer Business Overview
        11.16.3 Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.16.4 Perkin Elmer Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
        11.16.5 Perkin Elmer Recent Development
    11.17 Pacific Bioscience
        11.17.1 Pacific Bioscience Company Detail
        11.17.2 Pacific Bioscience Business Overview
        11.17.3 Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.17.4 Pacific Bioscience Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
        11.17.5 Pacific Bioscience Recent Development
    11.18 Partek
        11.18.1 Partek Company Detail
        11.18.2 Partek Business Overview
        11.18.3 Partek Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.18.4 Partek Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
        11.18.5 Partek Recent Development
    11.19 GnuBIO
        11.19.1 GnuBIO Company Detail
        11.19.2 GnuBIO Business Overview
        11.19.3 GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.19.4 GnuBIO Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
        11.19.5 GnuBIO Recent Development
    11.20 Foundation Medicine
        11.20.1 Foundation Medicine Company Detail
        11.20.2 Foundation Medicine Business Overview
        11.20.3 Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.20.4 Foundation Medicine Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
        11.20.5 Foundation Medicine Recent Development
    11.21 Paradigm
        11.21.1 Paradigm Company Detail
        11.21.2 Paradigm Business Overview
        11.21.3 Paradigm Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.21.4 Paradigm Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
        11.21.5 Paradigm Recent Development
    11.22 Caris Life Sciences
        11.22.1 Caris Life Sciences Company Detail
        11.22.2 Caris Life Sciences Business Overview
        11.22.3 Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.22.4 Caris Life Sciences Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
        11.22.5 Caris Life Sciences Recent Development
    11.23 Myriad Genetics
        11.23.1 Myriad Genetics Company Detail
        11.23.2 Myriad Genetics Business Overview
        11.23.3 Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Introduction
        11.23.4 Myriad Genetics Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
        11.23.5 Myriad Genetics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details
List of Tables
    Table 1. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
    Table 2. Key Players of NGS Pre-Sequencing
    Table 3. Key Players of Sequencing
    Table 4. Key Players of NGS Data Analysis
    Table 5. Key Players of Primary, Secondary & Tertiary Data Analysis
    Table 6. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
    Table 7. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 8. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region (2018-2023) & (US$ Million)
    Table 9. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Region (2018-2023)
    Table 10. Global Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Region (2024-2029) & (US$ Million)
    Table 11. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Region (2024-2029)
    Table 12. Clinical Oncology Next Generation Sequencing (NGS) Market Trends
    Table 13. Clinical Oncology Next Generation Sequencing (NGS) Market Drivers
    Table 14. Clinical Oncology Next Generation Sequencing (NGS) Market Challenges
    Table 15. Clinical Oncology Next Generation Sequencing (NGS) Market Restraints
    Table 16. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue by Players (2018-2023) & (US$ Million)
    Table 17. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Players (2018-2023)
    Table 18. Global Top Clinical Oncology Next Generation Sequencing (NGS) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Clinical Oncology Next Generation Sequencing (NGS) as of 2022)
    Table 19. Ranking of Global Top Clinical Oncology Next Generation Sequencing (NGS) Companies by Revenue (US$ Million) in 2022
    Table 20. Global 5 Largest Players Market Share by Clinical Oncology Next Generation Sequencing (NGS) Revenue (CR5 and HHI) & (2018-2023)
    Table 21. Key Players Headquarters and Area Served
    Table 22. Key Players Clinical Oncology Next Generation Sequencing (NGS) Product Solution and Service
    Table 23. Date of Enter into Clinical Oncology Next Generation Sequencing (NGS) Market
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2018-2023) & (US$ Million)
    Table 26. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Type (2018-2023)
    Table 27. Global Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Type (2024-2029) & (US$ Million)
    Table 28. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Type (2024-2029)
    Table 29. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2018-2023) & (US$ Million)
    Table 30. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Application (2018-2023)
    Table 31. Global Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Application (2024-2029) & (US$ Million)
    Table 32. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Application (2024-2029)
    Table 33. North America Clinical Oncology Next Generation Sequencing (NGS) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 34. North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2018-2023) & (US$ Million)
    Table 35. North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2024-2029) & (US$ Million)
    Table 36. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 37. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2018-2023) & (US$ Million)
    Table 38. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2024-2029) & (US$ Million)
    Table 39. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 40. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region (2018-2023) & (US$ Million)
    Table 41. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region (2024-2029) & (US$ Million)
    Table 42. Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 43. Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2018-2023) & (US$ Million)
    Table 44. Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2024-2029) & (US$ Million)
    Table 45. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 46. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2018-2023) & (US$ Million)
    Table 47. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2024-2029) & (US$ Million)
    Table 48. Illumina Company Detail
    Table 49. Illumina Business Overview
    Table 50. Illumina Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 51. Illumina Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
    Table 52. Illumina Recent Development
    Table 53. Roche Company Detail
    Table 54. Roche Business Overview
    Table 55. Roche Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 56. Roche Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
    Table 57. Roche Recent Development
    Table 58. Agilent Technologies Company Detail
    Table 59. Agilent Technologies Business Overview
    Table 60. Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 61. Agilent Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
    Table 62. Agilent Technologies Recent Development
    Table 63. Knome Company Detail
    Table 64. Knome Business Overview
    Table 65. Knome Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 66. Knome Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
    Table 67. Knome Recent Development
    Table 68. Genomatix Software Company Detail
    Table 69. Genomatix Software Business Overview
    Table 70. Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 71. Genomatix Software Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
    Table 72. Genomatix Software Recent Development
    Table 73. GATC Biotech Company Detail
    Table 74. GATC Biotech Business Overview
    Table 75. GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 76. GATC Biotech Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
    Table 77. GATC Biotech Recent Development
    Table 78. Oxford Nanopore Technologies Company Detail
    Table 79. Oxford Nanopore Technologies Business Overview
    Table 80. Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 81. Oxford Nanopore Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
    Table 82. Oxford Nanopore Technologies Recent Development
    Table 83. Macrogen Company Detail
    Table 84. Macrogen Business Overview
    Table 85. Macrogen Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 86. Macrogen Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
    Table 87. Macrogen Recent Development
    Table 88. Life Technologies Company Detail
    Table 89. Life Technologies Business Overview
    Table 90. Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 91. Life Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
    Table 92. Life Technologies Recent Development
    Table 93. DNASTAR Company Detail
    Table 94. DNASTAR Business Overview
    Table 95. DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 96. DNASTAR Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
    Table 97. DNASTAR Recent Development
    Table 98. Exosome Diagnostics Company Detail
    Table 99. Exosome Diagnostics Business Overview
    Table 100. Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 101. Exosome Diagnostics Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
    Table 102. Exosome Diagnostics Recent Development
    Table 103. Biomatters Company Detail
    Table 104. Biomatters Business Overview
    Table 105. Biomatters Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 106. Biomatters Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
    Table 107. Biomatters Recent Development
    Table 108. CLC Bio Company Detail
    Table 109. CLC Bio Business Overview
    Table 110. CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 111. CLC Bio Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
    Table 112. CLC Bio Recent Development
    Table 113. BGI Company Detail
    Table 114. BGI Business Overview
    Table 115. BGI Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 116. BGI Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
    Table 117. BGI Recent Development
    Table 118. Qiagen Company Detail
    Table 119. Qiagen Business Overview
    Table 120. Qiagen Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 121. Qiagen Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
    Table 122. Qiagen Recent Development
    Table 123. Perkin Elmer Company Detail
    Table 124. Perkin Elmer Business Overview
    Table 125. Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 126. Perkin Elmer Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
    Table 127. Perkin Elmer Recent Development
    Table 128. Pacific Bioscience Company Detail
    Table 129. Pacific Bioscience Business Overview
    Table 130. Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 131. Pacific Bioscience Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
    Table 132. Pacific Bioscience Recent Development
    Table 133. Partek Company Detail
    Table 134. Partek Business Overview
    Table 135. Partek Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 136. Partek Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
    Table 137. Partek Recent Development
    Table 138. GnuBIO Company Detail
    Table 139. GnuBIO Business Overview
    Table 140. GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 141. GnuBIO Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
    Table 142. GnuBIO Recent Development
    Table 143. Foundation Medicine Company Detail
    Table 144. Foundation Medicine Business Overview
    Table 145. Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 146. Foundation Medicine Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
    Table 147. Foundation Medicine Recent Development
    Table 148. Paradigm Company Detail
    Table 149. Paradigm Business Overview
    Table 150. Paradigm Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 151. Paradigm Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
    Table 152. Paradigm Recent Development
    Table 153. Caris Life Sciences Company Detail
    Table 154. Caris Life Sciences Business Overview
    Table 155. Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 156. Caris Life Sciences Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
    Table 157. Caris Life Sciences Recent Development
    Table 158. Myriad Genetics Company Detail
    Table 159. Myriad Genetics Business Overview
    Table 160. Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Product
    Table 161. Myriad Genetics Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023) & (US$ Million)
    Table 162. Myriad Genetics Recent Development
    Table 163. Research Programs/Design for This Report
    Table 164. Key Data Information from Secondary Sources
    Table 165. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Comparison by Type (2023-2029) & (US$ Million)
    Figure 2. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Type: 2022 VS 2029
    Figure 3. NGS Pre-Sequencing Features
    Figure 4. Sequencing Features
    Figure 5. NGS Data Analysis Features
    Figure 6. Primary, Secondary & Tertiary Data Analysis Features
    Figure 7. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Comparison by Application (2023-2029) & (US$ Million)
    Figure 8. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Application: 2022 VS 2029
    Figure 9. Academic & Clinical Research Case Studies
    Figure 10. Hospitals & Clinics Case Studies
    Figure 11. Pharma & Biotech Entities Case Studies
    Figure 12. Clinical Oncology Next Generation Sequencing (NGS) Report Years Considered
    Figure 13. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size (US$ Million), Year-over-Year: 2018-2029
    Figure 14. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size, (US$ Million), 2018 VS 2022 VS 2029
    Figure 15. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Region: 2022 VS 2029
    Figure 16. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Players in 2022
    Figure 17. Global Top Clinical Oncology Next Generation Sequencing (NGS) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Clinical Oncology Next Generation Sequencing (NGS) as of 2022)
    Figure 18. The Top 10 and 5 Players Market Share by Clinical Oncology Next Generation Sequencing (NGS) Revenue in 2022
    Figure 19. North America Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 20. North America Clinical Oncology Next Generation Sequencing (NGS) Market Share by Country (2018-2029)
    Figure 21. United States Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 22. Canada Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 23. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 24. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Share by Country (2018-2029)
    Figure 25. Germany Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 26. France Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 27. U.K. Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 28. Italy Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 29. Russia Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 30. Nordic Countries Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 31. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 32. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Share by Region (2018-2029)
    Figure 33. China Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 34. Japan Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 35. South Korea Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 36. Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 37. India Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 38. Australia Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 39. Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 40. Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Share by Country (2018-2029)
    Figure 41. Mexico Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 42. Brazil Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 43. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 44. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Share by Country (2018-2029)
    Figure 45. Turkey Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 46. Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 47. Illumina Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
    Figure 48. Roche Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
    Figure 49. Agilent Technologies Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
    Figure 50. Knome Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
    Figure 51. Genomatix Software Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
    Figure 52. GATC Biotech Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
    Figure 53. Oxford Nanopore Technologies Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
    Figure 54. Macrogen Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
    Figure 55. Life Technologies Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
    Figure 56. DNASTAR Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
    Figure 57. Exosome Diagnostics Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
    Figure 58. Biomatters Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
    Figure 59. CLC Bio Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
    Figure 60. BGI Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
    Figure 61. Qiagen Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
    Figure 62. Perkin Elmer Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
    Figure 63. Pacific Bioscience Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
    Figure 64. Partek Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
    Figure 65. GnuBIO Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
    Figure 66. Foundation Medicine Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
    Figure 67. Paradigm Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
    Figure 68. Caris Life Sciences Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
    Figure 69. Myriad Genetics Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2018-2023)
    Figure 70. Bottom-up and Top-down Approaches for This Report
    Figure 71. Data Triangulation
    Figure 72. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Illumina
Roche
Agilent Technologies
Knome
Genomatix Software
GATC Biotech
Oxford Nanopore Technologies
Macrogen
Life Technologies
DNASTAR
Exosome Diagnostics
Biomatters
CLC Bio
BGI
Qiagen
Perkin Elmer
Pacific Bioscience
Partek
GnuBIO
Foundation Medicine
Paradigm
Caris Life Sciences
Myriad Genetics
Frequently Asked Questions
Clinical Oncology Next Generation Sequencing (NGS) report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Clinical Oncology Next Generation Sequencing (NGS) report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Clinical Oncology Next Generation Sequencing (NGS) report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Cloud Based Storage

This report aims to provide a comprehensive presentation of the global market for Cloud Based Sto ... Read More